| Literature DB >> 24825008 |
Julia Dubois1, Olivier Terrier2, Manuel Rosa-Calatrava2.
Abstract
During their nuclear replication stage, influenza viruses hijack the host splicing machinery to process some of their RNA segments, the M and NS segments. In this review, we provide an overview of the current knowledge gathered on this interplay between influenza viruses and the cellular spliceosome, with a particular focus on influenza A viruses (IAV). These viruses have developed accurate regulation mechanisms to reassign the host spliceosome to alter host cellular expression and enable an optimal expression of specific spliced viral products throughout infection. Moreover, IAV segments undergoing splicing display high levels of similarity with human consensus splice sites and their viral transcripts show noteworthy secondary structures. Sequence alignments and consensus analyses, along with recently published studies, suggest both conservation and evolution of viral splice site sequences and structure for improved adaptation to the host. Altogether, these results emphasize the ability of IAV to be well adapted to the host's splicing machinery, and further investigations may contribute to a better understanding of splicing regulation with regard to viral replication, host range, and pathogenesis.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24825008 PMCID: PMC4030477 DOI: 10.1128/mBio.00070-14
Source DB: PubMed Journal: mBio Impact factor: 7.867
FIG 1 (A) Influenza A virus (IAV) particle. The IAV genome is composed of eight ribonucleoprotein complexes (vRNPs). Each one consists of single-stranded negative-sense viral RNA (vRNA) encapsidated by viral nucleoprotein (NP) and a viral polymerase complex (PA, PB1, and PB2) positioned at the extremity of the vRNA segment (depicted at top right). Three viral proteins are embedded within the viral membrane, hemagglutinin (HA), neuraminidase (NA), and ion channel protein (M2). Matrix protein 1 (M1) underlies the viral envelope and holds the vRNPs inside the virion. NS2/NEP is involved in vRNP packaging into viral particles and remains inside, and it is associated with M1. (B) Influenza viral cycle. The viral particle binds to sialic acid receptors and enters the cell via receptor-mediated endocytosis. Acidification of the endocytic vesicles leads to virus uncoating mediated by the M2 ion channel. vRNPs are then released into the cytoplasm and transported into the nucleus. There, the viral RNA-dependent RNA polymerase complex snatches the host mRNA caps (red line) to initiate the negative vRNA [vRNA(-)] transcription. Transcribed vRNAs then need to undergo an mRNA maturation phase, including the pre-mRNA splicing (depicted in dotted-line box), before export to the cytoplasm to be translated. vRNAs are also replicated in the nucleus to generate new vRNPs in association with neosynthesized viral proteins. Progeny vRNPs are transported toward the cytoplasmic membrane with viral components to be packaged into new infectious particles which are formed by cellular envelope budding. Panels A and B are based on data from reference 3. (C) Coilin is used as an example to show IAV-induced modifications of host splicing factors in the nucleus. A549 cells were infected with influenza virus A/Moscow/10/99 (H3N2) at a multiplicity of infection of 0.1 for 24 h, fixed, and immunostained to study the localization of IAV NS1 (green) and coilin (red). DAPI was used to stain cell nuclei (blue). Coilin expression is strongly affected within infected cells compared with its expression in noninfected cells (well-defined spots).
FIG 2 Classical signals, effectors, and regulators of pre-mRNA splicing in human cells. Four intronic motifs are required for splicing of pre-mRNA: the donor site GU at the intronic 5′ end (5′ ss), the branch point A, the polypyrimidine tract (Y)n upstream from the acceptor site AG dinucleotide at the intronic 3′ end, and the acceptor splice site (3′ ss). The sequences surrounding both the donor and acceptor dinucleotides are highly conserved, as illustrated by the consensus sequence representations (20). For each sequence motif, the size of a nucleotide is proportional to its frequency at the given position obtained from sequence alignments. Colored nucleotides show the exon-intron boundaries. The spliceosome is composed of small nuclear RNAs and polypeptides in small nuclear ribonucleoproteins (snRNPs), including the subunit U1, U2, U4, U5, and U6 snRNPs. In the first stages, U1 snRNP binds to the acceptor site and U2 snRNP to the donor site, and then, with the help of splicing factors such as U2AF, the other subunits are recruited. The splicing process is also directed by the action of numerous regulators, which are serine–arginine-rich proteins (SR proteins), such as SRp40, SRp55, and SF2/ASF, and heterogeneous nuclear ribonucleoproteins (hnRNPs). Splicing regulators recognize cis elements in the pre-mRNA sequence. SR proteins bind to enhancing signals, whereas hnRNPs recognize silencing ones (100). ESS, exonic splicing silencer; ISS, intronic splicing silencer; ISE, intronic splicing enhancer; ESE, exonic splicing enhancer.
FIG 3 Splicing of influenza NS and M segments. (A) There are up to three overlapping coding sequences in the NS segment. A full-length NS transcript is usually 864 nucleotides (nt) long and is terminated by a short polyadenylation motif at the 3′ extremity. NS1 protein is encoded by a colinear transcript from the initiation codon at position 27–29 to the termination codon at position 738–740. NS2/NEP protein is encoded by an interrupted transcript that is identical to the first section of the NS1 transcript (up to position 56), with a second section that is similar to the end of the NS segment from position 526 to 864. The black boxes at the 5′ ends represent leader nonviral sequences of 10 or 11 nt. The viral transcript encoding NS3 contains a novel 5′ ss (GG/GUA) and the same 3′ ss as NS2 mRNA. This novel 5′ ss was only observed in a limited number of IAV strain sequences. The noncoding and coding sequences are represented as thin lines and colored boxes, respectively. The positions and sequences of both splice sites are detailed. “A(n)” at the 3′ extremity is the polyadenylation motif. Consensus motifs corresponding to the 5′ ss and 3′ ss were generated using weblogo (http://weblogo.berkeley.edu/) (101) from a sequence alignment of 541 complete NS sequences (human and avian origin, 2011 to 2012) obtained from the Influenza Research Database (http://www.fludb.org/) (102). (B) One M segment template has four transcripts. The full-length M transcript is 1,004 nt. The M1 protein is encoded by the colinear transcript from the initiation codon at position 26–28 to the termination codon at position 782–784. The M2 protein originates from the interrupted mRNA M2, which has a sequence in common with that of the mRNA M1 until position 51 and then, at the 3′ end, consists of the full-length transcript from position 740. mRNA M2 shares the same initiation codon with mRNA M1 but switches to another open reading frame (ORF) in the last part of the mRNA. mRNA3 is interrupted from position 11 to 740, and mRNA M4 from position 145 to 740. Only mRNA M4 codes for a third protein (M42), using another initiation codon at position 114–116. Black boxes at the 5′ ends represent nonviral leader sequences of 10 or 11 nt. The noncoding and coding sequences are represented as thin lines and colored boxes, respectively. The positions and sequences of all efficient splice sites are detailed. “A(n)” at the 3′ extremity is the polyadenylation motif. Using the same methodology as described in the legend to panel A, consensus motifs for the different 5′ ss and the 3′ ss were obtained from sequence alignment of 669 complete M sequences (human and avian origin, 2011 to 2012) obtained from the Influenza Research Database. (A and B) Stars above the mRNA NS3 and mRNA M4 consensus sequences indicate the positions of mutations described in the literature. Nucleotide positions are based on A/Udorn/72 (H3N2) sequences.
FIG 4 Model of the regulation of segment M splicing. (A) Blocking of distal 5′ ss. The switch from the distal mRNA3 5′ ss (11 nt) to the proximal M2 alternative 5′ ss (51 nt) by obstruction of the spliceosome binding by a viral product (viral polymerase complex or NS1 protein) is depicted. (B) Selection of the alternative 5′ ss is obtained by stabilization of the SF2/ASF interaction in the 3′ ss region. SF2/ASF recognizes an exonic splicing enhancer (ESE) composed of a purine-rich sequence (shown in red). (C) Stable secondary structures formed around the 3′ ss region. (i) Hairpin conformation opens access to the branch point site (A, highlighted in purple) and 3′ ss (red arrowhead) for the spliceosome assembly and to the ESE motif (orange line) for the SF2/ASF factor. (ii) Pseudoknot conformation tends to prevent 3′-ss processing by the spliceosome.
List of cellular splicing factors identified using high-throughput approaches that are important for viral replication
| High-throughput approach(es) used | Cellular factor identified | Complete name | Influenza virus(es)—cellular model(s) | Reference |
|---|---|---|---|---|
| Genome-wide RNAi screening | AQR | Aquarius homolog (mouse) | A/Puerto Rico/8/34 (H1N1)—U2OS cells, modified A/WSN/33 (H1N1)—D-Mel2 | |
| BCAS2 | Breast carcinoma amplified sequence 2 | Modified A/WSN/33 (H1N1)—D-Mel2 | ||
| C19orf29 | Cactin | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| CLK1 | CDC-like kinase 1 | A/Puerto Rico/8/34 (H1N1)—U2OS cells, A/WSN/33 (H1N1)—A549 cells | ||
| CLK3 | CDC-like kinase 3, dual-specificity protein kinase CLK3 | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| CRNKL1 | Crooked neck pre-mRNA splicing factor-like 1 ( | |||
| CWC22 | Pre-mRNA-splicing factor CWC22 homolog | |||
| DHX8 | ATP-dependent RNA helicase DHX8 | |||
| EFTUD2 | Elongation factor Tu GTP binding domain containing 2 | |||
| FUS | Fused in sarcoma (HNRNPP2) | |||
| HNRNPA1 | Heterogeneous nuclear ribonucleoprotein A1 | Modified A/WSN/33 (H1N1)—D-Mel2 | ||
| HNRNPU | Heterogeneous nuclear ribonucleoprotein U | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| LSM2 | LSM2 homolog, U6 small nuclear RNA associated | |||
| NHP2L1 | NHP2 nonhistone chromosome protein 2-like 1 | A/Puerto Rico/8/34 (H1N1)—U2OS cells, A/WSN/33 (H1N1)—A549 cells | ||
| POLR2H | Polymerase (RNA) II (DNA directed) polypeptide H | A/WSN/33 (H1N1)—A549 cells | ||
| POLR2L | Polymerase (RNA) II (DNA directed) polypeptide L, 7.6 kDa | |||
| PPAN | Peter pan homolog ( | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| PPWD1 | Peptidylprolyl isomerase domain and WD repeat-containing 1 | Modified A/WSN/33 (H1N1)—D-Mel2 | ||
| PRPF31 | PRP31 pre-mRNA processing factor 31 homolog | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| PRPF8 | PRP8 pre-mRNA processing factor 8 homolog | A/Puerto Rico/8/34 (H1N1)—U2OS cells, A/WSN/33 (H1N1)—A549 cells | ||
| RBM5 | RNA binding motif protein 5 | A/WSN/33 (H1N1)—A549 cells | ||
| RNPS1 | RNA binding protein S1, serine-rich domain | Modified A/WSN/33 (H1N1)—D-Mel2 | ||
| SART1 | Squamous cell carcinoma antigen recognized by T cells | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| SF3A1 | Splicing factor 3a, subunit 1, 120 kDa | A/WSN/33 (H1N1)—A549 cells, A/WSN/33 (H1N1)—A549 cells | ||
| SF3B1 | Splicing factor 3b, subunit 1, 155 kDa | A/Puerto Rico/8/34 (H1N1)—U2OS cells, A/WSN/33 (H1N1)—A549 cells | ||
| SF3B14 | Splicing factor 3b, 14-kDa subunit | A/WSN/33 (H1N1)—A549 cells | ||
| SF3B2 | Splicing factor 3b, subunit 2, 145 kDa | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| SF3B3 | Splicing factor 3b, subunit 3, 130 kDa | |||
| SLU7 | Pre-mRNA-splicing factor SLU7 | |||
| SNRP70 | Small nuclear ribonucleoprotein 70-kDa polypeptide (RNP antigen) | A/WSN/33 (H1N1)—A549 cells, A/WSN/33 (H1N1)—A549 cells | ||
| SNRPA1 | Small nuclear ribonucleoprotein polypeptide A′ | A/WSN/33 (H1N1)—A549 cells | ||
| SNRPB | Small nuclear ribonucleoprotein polypeptides B and B1 | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| SNRPC | Small nuclear ribonucleoprotein polypeptide C | Modified A/WSN/33 (H1N1)—D-Mel2 | ||
| SNRPD1 | Small nuclear ribonucleoprotein D1 polypeptide, 16 kDa | |||
| SNRPD2 | Small nuclear ribonucleoprotein D2 polypeptide, 16.5 kDa | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| SNRPD3 | Small nuclear ribonucleoprotein D3 polypeptide, 18 kDa | |||
| SNRPF | Small nuclear ribonucleoprotein polypeptide F | A/WSN/33 (H1N1)—A549 cells | ||
| SNRPG | Small nuclear ribonucleoprotein polypeptide G | Modified A/WSN/33 (H1N1)—D-Mel2 | ||
| THOC4 | THO complex 4 | |||
| TXNL4A | Thioredoxin-like 4A | A/WSN/33 (H1N1)—A549 cells | ||
| YTHDC1 | Putative splicing factor YT521 | A/Puerto Rico/8/34 (H1N1)—U2OS cells | ||
| Genome-wide RNAi screening, random homozygous gene perturbation | PTBP1 | Polypyrimidine tract-binding protein 1 | A/Puerto Rico/8/34 (H1N1)—U2OS cells, A/Udorn/72 (H3N2)—MDCK cells | |
| Random homozygous gene perturbation | DDX17 | DEAD (Asp–Glu–Ala–Asp) box polypeptide 17 | A/Udorn/72 (H3N2)—MDCK cells | |
| LSM4 | LSM4 homolog, U6 small nuclear RNA associated ( | |||
| PAPOLA | Poly(A) polymerase alpha | |||
| SF3A3 | Splicing factor 3a, subunit 3, 60 kDa | |||
| SNW1 | SNW domain-containing 1 | |||
| Yeast two-hybrid system, siRNA screening | UAP56 | DEAD (Asp–Glu–Ala–Asp) box polypeptide 39B | A/Puerto Rico/8/34 (H1N1) HeLa Cells, A/Bratislava/79/H7N7 (H7N7)—A549 and 293T cells |